Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Entero Therapeutics (ENTO) just unveiled an announcement.
Timothy R. Ramdeen, a seasoned professional with nearly a decade of experience in private equity, hedge fund investing, and company formation, has been appointed to the Board of a company. He is the founder of Dharma Capital Advisors and has played significant roles in various investment and biotechnology firms, including Sixth Borough Capital Management and Amplexd Therapeutics. Ramdeen, who holds a B.S. in Biology and an MBA in Finance, adds considerable life science industry expertise to the Board. Additionally, the company has seen recent changes to its Audit and Compensation Committees following the resignations of previous members, with new appointments to fill these roles.
Find detailed analytics on ENTO stock on TipRanks’ Stock Analysis page.